ES2983338T3 - Una composición que se une al receptor del factor de crecimiento de hepatocitos (HGFR) para uso en un método de tratamiento de la neblina o la cicatrización corneal - Google Patents

Una composición que se une al receptor del factor de crecimiento de hepatocitos (HGFR) para uso en un método de tratamiento de la neblina o la cicatrización corneal Download PDF

Info

Publication number
ES2983338T3
ES2983338T3 ES16845118T ES16845118T ES2983338T3 ES 2983338 T3 ES2983338 T3 ES 2983338T3 ES 16845118 T ES16845118 T ES 16845118T ES 16845118 T ES16845118 T ES 16845118T ES 2983338 T3 ES2983338 T3 ES 2983338T3
Authority
ES
Spain
Prior art keywords
hgf
growth factor
corneal
hepatocyte growth
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES16845118T
Other languages
English (en)
Spanish (es)
Inventor
Sunil Chauhan
Reza Dana
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Schepens Eye Research Institute Inc
Original Assignee
Schepens Eye Research Institute Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schepens Eye Research Institute Inc filed Critical Schepens Eye Research Institute Inc
Application granted granted Critical
Publication of ES2983338T3 publication Critical patent/ES2983338T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1833—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4753—Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
ES16845118T 2015-09-11 2016-09-09 Una composición que se une al receptor del factor de crecimiento de hepatocitos (HGFR) para uso en un método de tratamiento de la neblina o la cicatrización corneal Active ES2983338T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562217611P 2015-09-11 2015-09-11
PCT/US2016/050945 WO2017044743A1 (en) 2015-09-11 2016-09-09 Compositions and methods for prevention and treatment of corneal haze and scarring

Publications (1)

Publication Number Publication Date
ES2983338T3 true ES2983338T3 (es) 2024-10-22

Family

ID=58240852

Family Applications (1)

Application Number Title Priority Date Filing Date
ES16845118T Active ES2983338T3 (es) 2015-09-11 2016-09-09 Una composición que se une al receptor del factor de crecimiento de hepatocitos (HGFR) para uso en un método de tratamiento de la neblina o la cicatrización corneal

Country Status (7)

Country Link
US (4) US10449234B2 (https=)
EP (2) EP3347034B1 (https=)
JP (4) JP6929273B2 (https=)
AU (3) AU2016320905B2 (https=)
CA (1) CA2999511C (https=)
ES (1) ES2983338T3 (https=)
WO (1) WO2017044743A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2999511C (en) 2015-09-11 2024-01-23 The Schepens Eye Research Institute, Inc. Compositions and methods for prevention and treatment of corneal haze and scarring
WO2019155833A1 (ja) * 2018-02-07 2019-08-15 学校法人日本医科大学 改良型アデノ随伴ウイルスベクター
EP3863715A4 (en) * 2018-10-09 2022-08-24 The Board of Trustees of the Leland Stanford Junior University MODIFIED FIBROBLASTIC GROWTH FACTOR VARIANTS COMBINED WITH MODIFIED HEPATOCYTE GROWTH FACTOR VARIANTS FOR THERAPY
WO2020185689A1 (en) * 2019-03-08 2020-09-17 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Multilayer drug delivery coating for contact lens
EP3962511A4 (en) * 2019-04-29 2023-01-18 The Board of Trustees of the Leland Stanford Junior University METHODS OF OCULAR TREATMENT USING A GENETICALLY MODIFIED HEPATOCYTE GROWTH FACTOR DIMERIC FRAGMENT
EP4574211A3 (en) 2021-05-14 2025-09-10 Claris Biotherapeutics, Inc. Compositions of growth factor for the treatment of eye disease

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6566098B1 (en) * 1990-09-14 2003-05-20 The United States Of America As Represented By The Department Of Health And Human Services DNA encoding truncated hepatocyte growth factor variants
US5703047A (en) * 1992-09-21 1997-12-30 Board Of Regents, The University Of Texas System Methods and treatments for corneal healing with growth factors
US5589451A (en) 1992-09-21 1996-12-31 Board Of Regents, The University Of Texas System Methods and treaments for corneal healing with hepatocyte and keratinocyte growth factors
JP3962097B2 (ja) * 1994-03-18 2007-08-22 敏一 中村 免疫抑制剤による副作用の軽減剤
US20020136721A1 (en) * 1998-02-17 2002-09-26 Schwall Ralph H. Hepatocyte growth factor receptor antagonists and uses thereof
AU2745599A (en) 1998-03-05 1999-09-20 Senju Pharmaceutical Co., Ltd. Pharmaceutical composition for prophylaxis and therapy of diseases associated with ocular fundus tissue cytopathy
US20030148950A1 (en) * 2001-10-09 2003-08-07 Li Xin Kringle domain 1 of human hepatocyte growth factor and uses therefor
US7202066B2 (en) * 2002-01-29 2007-04-10 Carrington Laboratories, Inc. Combination of a growth factor and a protease enzyme
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
US8575099B2 (en) * 2006-04-20 2013-11-05 Osaka University Agent for treating polyglutamine aggregation-caused disease or suppressing onset thereof
JP5093783B2 (ja) * 2006-04-20 2012-12-12 クリングルファーマ株式会社 Ｈｇｆ前駆体蛋白質改変体及びその活性型蛋白質
US20070167935A1 (en) * 2007-01-19 2007-07-19 Serdarevic Olivia N Methods and compositions for optimizing the outcomes of refractive laser surgery of the cornea
US9556248B2 (en) * 2010-03-19 2017-01-31 The Board Of Trustees Of The Leland Stanford Junior University Hepatocyte growth factor fragments that function as potent met receptor agonists and antagonists
HRP20191711T1 (hr) 2011-03-14 2019-12-13 Drug Delivery Solutions Ltd Oftalmološki pripravak
US8999938B2 (en) * 2013-06-21 2015-04-07 Gnt Llc Ophthalmic lipophilic drug delivery vehicle formulations
CA2999511C (en) 2015-09-11 2024-01-23 The Schepens Eye Research Institute, Inc. Compositions and methods for prevention and treatment of corneal haze and scarring

Also Published As

Publication number Publication date
EP3347034A4 (en) 2019-05-08
HK1258026A1 (en) 2019-11-01
EP4417259A3 (en) 2024-10-23
WO2017044743A1 (en) 2017-03-16
CA2999511C (en) 2024-01-23
US11759499B2 (en) 2023-09-19
US20180256685A1 (en) 2018-09-13
US20210299219A1 (en) 2021-09-30
JP2025181979A (ja) 2025-12-11
AU2021286438A1 (en) 2022-01-20
CA2999511A1 (en) 2017-03-16
JP2018526412A (ja) 2018-09-13
EP3347034B1 (en) 2024-05-29
AU2016320905A1 (en) 2018-04-05
JP2021181472A (ja) 2021-11-25
EP3347034A1 (en) 2018-07-18
EP3347034C0 (en) 2024-05-29
JP6929273B2 (ja) 2021-09-01
US10449234B2 (en) 2019-10-22
AU2021286438B2 (en) 2024-12-05
US20200121758A1 (en) 2020-04-23
AU2025201563A1 (en) 2025-03-27
JP2023179739A (ja) 2023-12-19
EP4417259A2 (en) 2024-08-21
US20240123032A1 (en) 2024-04-18
AU2016320905B2 (en) 2021-10-07

Similar Documents

Publication Publication Date Title
ES2983338T3 (es) Una composición que se une al receptor del factor de crecimiento de hepatocitos (HGFR) para uso en un método de tratamiento de la neblina o la cicatrización corneal
ES2460578T3 (es) Uso de EDTA+trometamina o de foto-potenciadores, asociados a la riboflavina, para la reticulación de la córnea en el tratamiento del queratocono o de otros trastornos ectásicos de la córnea
Huang et al. Combination of dexamethasone and Avastin® by supramolecular hydrogel attenuates the inflammatory corneal neovascularization in rat alkali burn model
ES2244831T3 (es) Composicion farmaceutica para aplicacion oftalmologica y rinologica.
ES2259727T3 (es) Agente oftalmico que contiene heparina.
CN101972470B (zh) 一种眼用原位凝胶
JP2002515858A (ja) 角膜移植に起因する疾患を処置するための殺菌／浸透性増強（ｂｐｉ）タンパク質
CN102639141A (zh) 用于预防和治疗黄斑变性、糖尿病性视网膜病变和糖尿病性黄斑水肿的组合物和方法
WO2016156639A1 (es) Formulación tópica oftálmica de antagonistas del receptor de la endotelina
EP3096777B1 (en) Goblet cell replacement therapy
KR101810156B1 (ko) 폴리에틸렌 글리콜 및 플라보노이드 나노복합체를 유효성분으로 함유하는 안구 건조증 예방 또는 치료용 조성물
KR102356603B1 (ko) 안구건조증 치료를 위한 레코플라본 함유 점안 조성물
ES2211197T3 (es) Uso de derivados de estaurosporina para tratar enfermedades neovasculares oculares.
KR20170123502A (ko) 콜라겐 및 색소 상피성 인자를 유효성분으로 함유하는 신생혈관질환 예방 또는 치료용 약학조성물
US20210059969A1 (en) Alpha-aminoadipate for treatment of vision loss and restoring sight
ES2895923T3 (es) Composición para prevención/tratamiento de daño corneal que comprende timosina beta 4 y ácido cítrico como ingredientes activos
US10780070B2 (en) Alpha-aminoadipate for treatment of vision loss and restoring sight
KR20230117342A (ko) 펩타이드 제제 및 이의 안과적 용도
CN118717959A (zh) Pedf多肽模拟物在眼表疾病中的用途
CN119384288A (zh) 用于治疗干眼症的包含pedf衍生短肽的组合物
WO2013148305A1 (en) Method for treating diabetic retinopathy
WO2023048174A1 (ja) 角膜疾患治療剤
US20050130888A1 (en) Metallothionein based neuronal therapeutic and therapeutic methods
WO2011054993A1 (es) Péptidos para el tratamiento de la hipertensión ocular y/o el glaucoma